ilShinbiobase (068330) Fundamentals 2026 — P/E 7.6x, Revenue Analysis | SniperIQ
ilShinbiobase (068330) is a KR-listed Industrials company in Industrial - Machinery with a market capitalization of ₩38.8B, trading at ₩930.00 on the KOE. This SniperIQ fundamentals page covers ilShinbiobase's valuation (P/E 7.6x, P/B 0.6x), profitability (net margin 33.7%), revenue (₩14.5B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is ilShinbiobase's market cap?
ilShinbiobase (068330) has a market capitalization of approximately ₩38.8B, trading at ₩930.00 on the KOE. Market cap moves with the live share price.
What is ilShinbiobase's P/E ratio?
ilShinbiobase's trailing twelve-month P/E ratio is 7.6x, with a price-to-book (P/B) of 0.6x. Valuation multiples are best compared with Industrials sector peers rather than read in isolation.
How profitable is ilShinbiobase?
ilShinbiobase runs a net profit margin of 33.7%, a gross margin of 52.5%, and an operating margin of 30.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does ilShinbiobase generate?
ilShinbiobase reported revenue of ₩14.5B for fiscal year 2025, with net income of ₩4.8B and earnings per share (EPS) of 115. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does ilShinbiobase pay a dividend?
ilShinbiobase offers a trailing dividend yield of about 0.8%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is ilShinbiobase financially healthy?
ilShinbiobase carries a debt-to-equity ratio of 0.00x and a current ratio of 8.32x, with a market beta of 0.65. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is ilShinbiobase a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For ilShinbiobase (068330) the key facts are: market cap ₩38.8B, P/E 7.6x, revenue ₩14.5B, 52-week range 905-2055. Weigh valuation, profitability, growth, and balance-sheet strength against Industrials peers and form your own view.
Track ilShinbiobase's full fundamentals live
Get ilShinbiobase's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.